Latest News Archive

Please select Category, Year, and then Month to display items

UFS plant scientists receive prestigious SAPBA awards

10 June 2020 | Story Leonie Bolleurs | Photo Supplied

Read More Collage — Prof Zakkie Pretorius, left, plays a significant role in providing pathology support to the plant breeding industry.Prof Liezel Herselman contributes to plant breeding in Southern Africa by training and mentoring the plant breeders of the future.

The Southern African Plant Breeders’ Association (SAPBA) recently bestowed prestigious awards upon Prof Zakkie Pretorius, Research Fellow in the Department of Plant Sciences at the University of the Free State (UFS), and Prof Liezel Herselman, Associate Professor in the same department. This institution strives to maintain high ethical standards and norms, contributing to stable, sustainable agriculture.

During the 13th Southern African Plant Breeders’ Association symposium, Prof Herselman was presented with a Fellow Award and Prof Pretorius with Honorary Membership. They received the awards for their services to and promotion of the SAPBA objectives, together with their exceptional contributions to plant breeding.

Provide food for the nation

Over the years, Prof Pretorius, who has extensive expertise in diseases of field crops – more specifically the rust diseases of small grain cereal crops – has played a significant role in providing pathology support to the plant breeding industry. He has also conducted ground-breaking pathology research on rust diseases in field crops. In 2019, he co-authored an article that appeared in Nature, the world’s leading multidisciplinary science journal. He is also shortlisted as a 2020 finalist in the Lifetime Award and Special Theme Award (Plant Health) of the National Science and Technology Forum. Furthermore, he regularly attended and participated in biennial conferences and supervised plant breeding students working on plant disease projects.

Prof Herselman contributes to plant breeding in Southern Africa by training and mentoring the plant breeders of the future. “As a lecturer of fourth-year and honours Plant Breeding students, as well as supervisor and promoter of master’s and doctoral students, I am in the fortunate position to teach and mentor my students in one of the newest fields of plant breeding, namely marker-assisted plant breeding. All future plant breeders need this knowledge to make a success of their breeding programmes. Our students are the future plant breeders who will provide food to the nation,” she says.

"As a plant pathologist, I am privileged to have been able to contribute to the quest for disease resistance in crop improvement and to have been recognised for it.” – Prof Zakkie Pretorius

The highest honour

Prof Pretorius view recognition by the industry – in this case, the plant breeding fraternity – as the highest honour for someone working in agricultural science. “As a plant pathologist, I am privileged to have been able to contribute to the quest for disease resistance in crop improvement and to have been recognised for it. I am also extremely grateful to colleagues and co-workers who have contributed over many years to the establishment of a productive and influential research group at the UFS,” he says.

Prof Herselman shares this sentiment. She says: “It means so much to me to know that I have made a difference and an impact on my students’ lives. It is a privilege to have the opportunity to work with under- and postgraduate students and to see them grow.”

She continues: “We strive to send out well-rounded students who can make a difference in the workplace and the community. This award means that I have succeeded in this goal, even though I do my work because I am passionate about it and not to receive recognition.”

Fight against fungal disease continues

Prof Pretorius continues to be involved in studies on host plant resistance and pathogenic variability.

As a molecular plant breeder, Prof Herselman is pushing on with research focusing on the development of wheat lines with improved disease resistance. The work that she is doing makes a difference on both national and international level. “As part of my current research programme, we have made rust- and Fusarium head blight-resistant wheat lines available to South African breeding companies for use in their breeding programmes. The lines developed at the UFS will in a small way contribute towards the fight against fungal diseases in South Africa, thus securing the yield and livelihoods of farmers and consumers,” she says.

Her master’s and doctoral students who have completed their studies, also take the knowledge they gained at the UFS back to their countries and workplaces where they ultimately add value, especially contributing towards the fight against hunger.

"“We strive to send out well-rounded students who can make a difference in the workplace and the community. This award means that I have succeeded in this goal, even though I do my work because I am passionate about it and not to receive recognition.” – Prof Liezel Herselman

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept